There are currently 48 active clinical trials seeking participants for Amyotrophic Lateral Sclerosis research studies. The states with the highest number of trials for Autism participants are California, Florida, Pennsylvania and New York.
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
NCT04363684
Recruiting
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/12/2024
Locations: University of Alabama Birmingham, Birmingham, Alabama +26 locations
Conditions: Frontotemporal Lobar Degeneration (FTLD), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Behavioral Variant Frontotemporal Dementia (bvFTD), Semantic Variant Primary Progressive Aphasia (svPPA), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), FTD With Amyotrophic Lateral Sclerosis (FTD/ALS), Amyotrophic Lateral Sclerosis, Oligosymptomatic PSP (oPSP), C9orf72, GRN Related Frontotemporal Dementia, MAPT Gene Mutation, TBK1 Gene Mutation, Oligosymptomatic Progressive Supranuclear Palsy
Register for Updates
Clinical Research in ALS Study
NCT00136500
Recruiting
CRiALS is an umbrella protocol through which people are recruited to participate in a range of research studies being conducted by the ALS Research Collaboration (ARC).
Gender:
All
Ages:
18 years and above
Trial Updated:
02/28/2024
Locations: University of Miami, Miami, Florida
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
The Pre-symptomatic Familial Amyotrophic Lateral Sclerosis (Pre-fALS) Study
NCT00317616
Recruiting
Pre-fALS is a prospective natural history and biomarker study of people not yet affected with ALS, but who are at genetic risk for developing ALS. The investigators aim to recruit unaffected (healthy) people from familial ALS (fALS) pedigrees in which a known genetic mutation associated with ALS has been identified; for this study, a fALS pedigree is one with two biologically related individuals who have or have had ALS and/or FTD. Individuals who may be at genetic risk for ALS and who belong to... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/28/2024
Locations: University of Miami, Miami, Florida
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
NCT00912041
Recruiting
The purpose of this study is to obtain preliminary device safety information and demonstrate proof of principle (feasibility) of the ability of people with tetraplegia to control a computer cursor and other assistive devices with their thoughts.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
02/26/2024
Locations: University of California, Davis, Sacramento, California +4 locations
Conditions: Tetraplegia, Spinal Cord Injuries, Amyotrophic Lateral Sclerosis, Brain Stem Infarctions, Locked in Syndrome, Muscular Dystrophy
Register for Updates
Regulatory T Cells for Amyotrophic Lateral Sclerosis
NCT05695521
Recruiting
Phase 1 Safety Run-in Study of 6 patients followed by Phase 1b Randomized, Double Blind, Placebo Control Trial of CK0803, neurotropic, allogeneic, umbilical cord blood derived T regulatory (Treg) cells in additional 60 patients with Amyotrophic Lateral Sclerosis.
Gender:
All
Ages:
Between 18 years and 95 years
Trial Updated:
02/16/2024
Locations: Columbia University Irving Medical Center, New York, New York +2 locations
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
Novel MRI Biomarkers for Monitoring Disease Progression in ALS
NCT03362658
Recruiting
Routine MRI is normal in motor neuron diseases such as ALS. However, advanced MRI techniques can provide an objective measure of degeneration (a "biomarker") by examining brain structure, wiring, chemistry, and function. We will develop and evaluate novel MRI techniques that could improve our understanding of ALS and provide a means to diagnose it sooner and monitor its progression. Importantly, we expect these techniques to improve how new drugs are tested, which may lead to the more rapid disc... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/16/2024
Locations: University of Miami, Miami, Florida +8 locations
Conditions: Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Register for Updates
Investigation on the Cortical Communication (CortiCom) System
NCT03567213
Recruiting
The CortiCom system consists of 510(k)-cleared components: platinum PMT subdural cortical electrode grids, a Blackrock Microsystems patient pedestal, and an external NeuroPort Neural Signal Processor. Up to two grids will be implanted in the brain, for a total channel count of up to 128 channels, for six months. In each participant, the grid(s) will be implanted over areas of cortex that encode speech and upper extremity movement.
Gender:
All
Ages:
Between 22 years and 70 years
Trial Updated:
02/07/2024
Locations: Johns Hopkins Medicine, Baltimore, Maryland
Conditions: Tetraplegia, Locked-in Syndrome, Brainstem Stroke, Amyotrophic Lateral Sclerosis
Register for Updates
The National Amyotrophic Lateral Sclerosis Registry
NCT01772602
Recruiting
The purpose of this registry is to (A) better describe the incidence and prevalence of Amyotrophic Lateral Sclerosis (ALS) in the United States;(B) examine appropriate factors, such as environmental and occupational, that may be associated with the disease; (C) better outline key demographic factors (such as age, race or ethnicity, gender, and family history of individuals who are diagnosed with the disease) associated with the disease; and (D) better examine the connection between ALS and other... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/06/2024
Locations: CDC, Atlanta, Georgia
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
CNS10-NPC-GDNF Delivered to the Motor Cortex for ALS
NCT05306457
Recruiting
The investigator is examining the safety of transplanting cells, that have been engineered to produce a growth factor, into the motor cortex (brain) of patients with Amyotrophic Lateral Sclerosis (ALS). The cells are called neural progenitor cells, which are a type of stem cell that can become several different types of cells in the nervous system. These cells have been derived to specifically become astrocytes, which is a type of neural cell. The growth factor is called glial cell line-derived... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/05/2024
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
A Mindful Community for People With ALS and Their Primary Caregivers
NCT05595850
Recruiting
The psychological impact of ALS on patients and caregivers is high, significantly affecting their quality of life (QOL). Despite this impact, there is not much research about psychological interventions that could reduce psychological distress and improve QOL. The efficacy of mindfulness-based treatments for the improvement of QOL was previously demonstrated by the investigator's group. Despite preliminary positive results, treatment efficacy tends to weaken over time. The investigators believe... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/13/2024
Locations: Harvard University, Cambridge, Massachusetts
Conditions: Amyotrophic Lateral Sclerosis, Caregiver Burden
Register for Updates
TJ-68 Clinical Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) and Muscle Cramps
NCT04998305
Recruiting
The primary objective of the study is to demonstrate the safety and potential efficacy of TJ-68 for improving muscle cramps in participants with ALS based on a two-site, randomized, placebo-controlled double-blind multi-period crossover (N-of-1) study design.
Gender:
All
Ages:
Between 20 years and 84 years
Trial Updated:
01/03/2024
Locations: Mayo Clinic, Scottsdale, Arizona +2 locations
Conditions: Amyotrophic Lateral Sclerosis, Muscle Cramp
Register for Updates
Biomarkers in Different Types of Amyotrophic Lateral Sclerosis (ALS) Patients Being Treated With Edaravone
NCT04097158
Recruiting
This study is being conducted to help the investigators better understand how the new FDA approved medication Edaravone (also known as Radicava) works in subsets of patients with ALS. The investigators are also trying to understand if there are specific ALS patients, with different presentations of ALS, who might benefit most from this medication. Also, the investigators are following specific biomarkers to determine the optimal treatment duration in patients with different forms of ALS There i... Read More
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
12/18/2023
Locations: Loma Linda University, Loma Linda, California
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates